https://news.augustaheadlines.com/story/530604/analysis-of-causes-for-overheating-in-fire-pump-motors.html 2025-08-14T11:14:03+00:00 daily 1.0 https://news.augustaheadlines.com/story/530603/which-multifunctional-mini-air-fryer-brands-stand-out-for-2025.html 2025-08-14T11:12:05+00:00 daily 1.0 https://news.augustaheadlines.com/story/530602/latin-food-fest-nyc-returns-as-the-culinary-flagship-of-hispanic-heritage-month-this-time-its-food-first-always.html 2025-08-14T11:00:05+00:00 daily 1.0 https://news.augustaheadlines.com/story/530601/thrombotic-thrombocytopenic-purpura-market-trends-point-to-steady-growth-ahead-by-2034-delveinsight-analysis-reveals-global-blood-therapeutics-sanofi-carelon-research-archemix-corp-eisai-inc.html 2025-08-14T10:54:03+00:00 daily 1.0 https://news.augustaheadlines.com/story/530600/atherosclerotic-cardiovascular-disease-market-expected-to-gain-momentum-through-2034-according-to-delveinsight-amgen-novo-nordisk-as-ionis-pharma-newamsterdam-pharma-resverlogixcorp-novartis.html 2025-08-14T10:30:04+00:00 daily 1.0 https://news.augustaheadlines.com/story/530599/nevada-northern-railway-unveils-locomotive-250-in-celebration-of-americas-250th-anniversary.html 2025-08-14T10:08:02+00:00 daily 1.0 https://news.augustaheadlines.com/story/530598/postpartum-depression-market-to-witness-promising-upswing-by-2034-delveinsight-forecasts-sage-therapeutics-brii-biosciences-limited-reunion-neuroscience-gh-research-bristolmyers-squibb.html 2025-08-14T09:52:02+00:00 daily 1.0 https://news.augustaheadlines.com/story/530597/fabry-disease-market-growth-to-surge-during-forecast-period-20242034-says-delveinsight-sanofi-genzyme-sangamo-therapeutics-freeline-therapeutics-avrobio-4d-molecular-therapeutics.html 2025-08-14T09:30:04+00:00 daily 1.0 https://news.augustaheadlines.com/story/530596/av-access-launches-bizeye-p30-a-4k-duallens-ptz-conference-camera-with-ai-tracking-for-smarter-hybrid-meetings.html 2025-08-14T09:04:02+00:00 daily 1.0 https://news.augustaheadlines.com/story/530595/graftversus-host-disease-market-set-for-robust-expansion-through-2034-delveinsight-reports-csl-behring-equillium-biocon-maat-pharma-regimmune-jazz-pharmaceuticals-pharmacyclics-novartis.html 2025-08-14T08:46:05+00:00 daily 1.0